Authors’ Reply to “Pituitary Atypical Adenoma or Carcinoma Sensitive to Temozolomide Combined with Radiation Therapy: A Case Report of Early Identification and Management”

References (1)

1. Curtò L, Torre ML, Ferraù F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavò S: Temozolomideinduced shrinkage of a pituitary carcinoma causing Cushing’s disease. Report of a case and literature review. Scientific World Journal 10: 2132-2138, 2010 2. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261–262, 2008 3. Raverot G, Castinetti F, Jouanneau E, Morange I, FigarellaBranger D, Dufour H, Trouillas J, Brue T: Pituitary carcinomas and aggressive pituitary tumours: Merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76:769–775, 2012 4. Zhong C, Yin S, Zhou P, Jiang S: Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: A case report of early identification and management. Turk Neurosurg 24:963-966, 2014